CCXI:NSD-ChemoCentryx, Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 62.36

Change

-4.44 (-6.65)%

Market Cap

USD 4.62B

Volume

0.51M

Average Target Price

USD 89.22 (+43.08%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

ChemoCentryx, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. Its lead drug candidate is Avacopan, an orally-administered complement inhibitor of the complement C5a receptor (C5aR), which is in Phase III development for the treatment of anti-neutrophil cytoplasmic auto-antibody-associated vasculitis; and Phase IIb clinical trial, the AURORA trial for the treatment of patients with moderate-to-severe hidradenitis suppurativa, as well as patients with complement 3 glomerulopathy. In addition, the company is developing CCX140, an inhibitor of the chemokine receptor known as CCR2, which has completed a Phase II clinical trial in diabetic nephropathy and is being developed for patients with focal segmental glomerulosclerosis; CCX507, a second generation CCR9 inhibitor, which has completed Phase I clinical trial; and CCX872, a potent and selective inhibitor of CCR2, which is in phase Ib clinical trial for the treatment of patients with stage 3 and 4 pancreatic cancer. ChemoCentryx, Inc. was founded in 1996 and is headquartered in Mountain View, California. Address: 850 Maude Avenue, Mountain View, CA, United States, 94043

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-03-03 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MRNA Moderna, Inc

-15.59 (-10.62%)

USD58.69B N/A N/A
VRTX Vertex Pharmaceuticals Incorpo..

-3.62 (-1.71%)

USD55.13B 20.61 15.08
REGN Regeneron Pharmaceuticals, Inc

-8.13 (-1.79%)

USD48.73B 14.90 11.87
ALXN Alexion Pharmaceuticals, Inc

-2.18 (-1.45%)

USD33.27B 55.63 33.22
BGNE BeiGene, Ltd

-1.91 (-0.62%)

USD29.03B N/A N/A
RPRX Royalty Pharma plc

-3.38 (-7.20%)

USD28.50B 22.60 14.17
SGEN Seagen Inc

-5.78 (-3.76%)

USD27.85B 45.61 37.70
BNTX BioNTech SE

-7.73 (-7.36%)

USD25.28B -99,999.99 N/A
GMAB Genmab A/S

-1.28 (-3.78%)

USD22.05B 26.59 3.17
IMMU Immunomedics, Inc

N/A

USD20.31B N/A N/A

ETFs Containing CCXI

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 0.71% 38% F 32% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 0.71% 38% F 32% F
Trailing 12 Months  
Capital Gain 22.80% 52% F 49% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 22.80% 51% F 48% F
Trailing 5 Years  
Capital Gain 1,712.79% 96% A 98% A+
Dividend Return N/A N/A N/A N/A N/A
Total Return 1,712.79% 96% A 98% A+
Average Annual (5 Year Horizon)  
Capital Gain 138.80% 93% A 96% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 138.80% 93% A 96% A
Risk Return Profile  
Volatility (Standard Deviation) 198.45% 11% F 6% F
Risk Adjusted Return 69.94% 91% A- 83% B
Market Capitalization 4.62B 90% A- 84% B
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 39.70 24% F 29% F
Price/Book Ratio 11.60 25% F 17% F
Price / Cash Flow Ratio -65.93 92% A- 92% A-
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -24.52% 83% B 33% F
Return on Invested Capital -97.00% 27% F 10% F
Return on Assets -9.47% 85% B 28% F
Debt to Equity Ratio 29.98% 36% F 56% F
Technical Ratios  
Short Ratio 6.48 25% F 14% F
Short Percent 6.91% 43% F 28% F
Beta 1.39 51% F 35% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters then its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.